Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody

Zhang, L; Geng, ZH; Hao, B; Geng, Q

Hao, B; Geng, Q (通讯作者)，Wuhan Univ, Dept Thorac Surg, Renmin Hosp, 238th Jiefang Rd, Wuhan 430060, Peoples R China.

CANCER CONTROL, 2022; 29 ():

Abstract

Tislelizumab is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G 4 antibody developed by BeiGene. The structure of tislelizumab ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索